Disclosed is the use of bifidobacterium and berberine in the preparation of a drug for treating pre-diabetes or type 2 diabetes. Specifically, it is suitable for pre-diabetes patients or type 2 diabetes patients that have 5.6≤ fasting plasma glucose (FPG) <8.0 mmol/L or 7.8≤ venous blood glucose at two hours after OGTT<17 mmol/L.